News
-
-
-
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics announces positive topline results from TEDOVA Phase 2 trial with Tedopi® in recurrent ovarian cancer, presenting at ASCO 2026. Combination with pembrolizumab improves progression-free survival -
-
-
-
-
COMMUNIQUÉ DE PRESSE
VARON Highlights Respiratory Wellness and Active Aging Ahead of Pentecost in Germany
VARON highlights the importance of respiratory wellness and active aging in Germany ahead of Pentecost, emphasizing mobility, safe travel, and oxygen health for older adults and individuals with breathing conditions -
COMMUNIQUÉ DE PRESSE
Interroll publishes Sustainability Report 2025
Interroll Holding AG publishes Sustainability Report 2025 highlighting commitment to responsible growth, governance, and value creation. Report covers People, Planet, Product pillars with focus on key sustainability topics and governance measures